These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 35452255)
1. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities. Vasic D; Lee JB; Leung Y; Khatri I; Na Y; Abate-Daga D; Zhang L Sci Immunol; 2022 Apr; 7(70):eabl3642. PubMed ID: 35452255 [TBL] [Abstract][Full Text] [Related]
2. Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells. Fang KK; Lee J; Khatri I; Na Y; Zhang L J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37678917 [TBL] [Abstract][Full Text] [Related]
3. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation]. Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464 [No Abstract] [Full Text] [Related]
4. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma. Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597 [TBL] [Abstract][Full Text] [Related]
5. Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15. Yao J; Ly D; Dervovic D; Fang L; Lee JB; Kang H; Wang YH; Pham NA; Pan H; Tsao MS; Zhang L J Immunother Cancer; 2019 Jan; 7(1):17. PubMed ID: 30670085 [TBL] [Abstract][Full Text] [Related]
6. CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation. Yan N; Wang N; Wang G; Huang L; Li C; Wang D; Wang J; Huang L; Meng F; Wei J; Chen L; Mao X; Zhou J; Zhang Y; Cao Y Cytotherapy; 2022 Aug; 24(8):841-849. PubMed ID: 35256277 [TBL] [Abstract][Full Text] [Related]
7. Good manufacturing practice-grade generation of CD19 and CD123-specific CAR-T cells using piggyBac transposon and allogeneic feeder cells in patients diagnosed with B-cell non-Hodgkin lymphoma and acute myeloid leukemia. Mucha M; Štach M; Kaštánková I; Rychlá J; Vydra J; Lesný P; Otáhal P Front Immunol; 2024; 15():1415328. PubMed ID: 39192973 [TBL] [Abstract][Full Text] [Related]
8. Allogeneic "Off-the-Shelf" CAR T cells: Challenges and advances. Chen S; van den Brink MRM Best Pract Res Clin Haematol; 2024 Sep; 37(3):101566. PubMed ID: 39396256 [TBL] [Abstract][Full Text] [Related]
9. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy. Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141 [TBL] [Abstract][Full Text] [Related]
10. Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review. Tang C; Zhang Y Pathol Res Pract; 2024 Oct; 262():155518. PubMed ID: 39146830 [TBL] [Abstract][Full Text] [Related]
11. Developing Allogeneic Double-Negative T Cells as a Novel Off-the-Shelf Adoptive Cellular Therapy for Cancer. Lee JB; Kang H; Fang L; D'Souza C; Adeyi O; Zhang L Clin Cancer Res; 2019 Apr; 25(7):2241-2253. PubMed ID: 30617140 [TBL] [Abstract][Full Text] [Related]
12. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Ottaviano G; Georgiadis C; Gkazi SA; Syed F; Zhan H; Etuk A; Preece R; Chu J; Kubat A; Adams S; Veys P; Vora A; Rao K; Qasim W; Sci Transl Med; 2022 Oct; 14(668):eabq3010. PubMed ID: 36288281 [TBL] [Abstract][Full Text] [Related]
13. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report. Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L Front Immunol; 2021; 12():728962. PubMed ID: 34691036 [TBL] [Abstract][Full Text] [Related]
14. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256 [TBL] [Abstract][Full Text] [Related]
15. [Construction and evaluation of dual-effect cord blood natural killer cells expressing highaffinity PD-1 and chimeric antigen CD19 receptor]. Zhong H; Zou Q; Liu H; Wang X; DU S; Liang H; Wu Z; Ye J; Zou Q Nan Fang Yi Ke Da Xue Xue Bao; 2021 Dec; 41(12):1877-1884. PubMed ID: 35012922 [TBL] [Abstract][Full Text] [Related]
16. The paths and challenges of "off-the-shelf" CAR-T cell therapy: An overview of clinical trials. Moradi V; Omidkhoda A; Ahmadbeigi N Biomed Pharmacother; 2023 Dec; 169():115888. PubMed ID: 37979380 [TBL] [Abstract][Full Text] [Related]
17. Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R/R ALL and NHL: A systematic review and meta-analysis. Chen S; Zhang Y; Fang C; Zhang N; Wang Y; Chen R; Li Y; Tu S Crit Rev Oncol Hematol; 2022 Nov; 179():103807. PubMed ID: 36087853 [TBL] [Abstract][Full Text] [Related]
18. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. Marcus A; Eshhar Z Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086 [TBL] [Abstract][Full Text] [Related]
19. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631 [TBL] [Abstract][Full Text] [Related]
20. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia. Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E Front Immunol; 2019; 10():3123. PubMed ID: 32117200 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]